Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Ovarian Cancer Treatment Stratification Using Ex Vivo Drug Sensitivity Testing.

Lohse I, Azzam DJ, Al-Ali H, Volmar CH, Brothers SP, Ince TA, Wahlestedt C.

Anticancer Res. 2019 Aug;39(8):4023-4030. doi: 10.21873/anticanres.13558.

PMID:
31366484
2.

Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer.

Mustafi S, Camarena V, Qureshi R, Yoon H, Volmar CH, Huff TC, Sant DW, Zheng L, Brothers SP, Wahlestedt C, Slingerland J, Wang G.

EBioMedicine. 2019 May;43:201-210. doi: 10.1016/j.ebiom.2019.04.006. Epub 2019 Apr 8.

3.

mRNA-to-protein translation in hypoxia.

Chee NT, Lohse I, Brothers SP.

Mol Cancer. 2019 Mar 30;18(1):49. doi: 10.1186/s12943-019-0968-4. Review.

4.

HDAC Inhibitors Induce BDNF Expression and Promote Neurite Outgrowth in Human Neural Progenitor Cells-Derived Neurons.

Bagheri A, Habibzadeh P, Razavipour SF, Volmar CH, Chee NT, Brothers SP, Wahlestedt C, Mowla SJ, Faghihi MA.

Int J Mol Sci. 2019 Mar 5;20(5). pii: E1109. doi: 10.3390/ijms20051109.

5.

BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.

Copsel SN, Lightbourn CO, Barreras H, Lohse I, Wolf D, Bader CS, Manov J, Kale BJ, Shah D, Brothers SP, Perez VL, Komanduri KV, Wahlestedt C, Levy RB.

Front Immunol. 2019 Jan 24;9:3104. doi: 10.3389/fimmu.2018.03104. eCollection 2018.

6.

Precision medicine in the treatment stratification of AML patients: challenges and progress.

Lohse I, Statz-Geary K, Brothers SP, Wahlestedt C.

Oncotarget. 2018 Dec 28;9(102):37790-37797. doi: 10.18632/oncotarget.26492. eCollection 2018 Dec 28. Review.

7.

Naturally occurring compounds as pancreatic cancer therapeutics.

Lohse I, Wildermuth E, Brothers SP.

Oncotarget. 2018 Oct 23;9(83):35448-35457. doi: 10.18632/oncotarget.26234. eCollection 2018 Oct 23. Review.

8.

Inhibition of HDAC3 reverses Alzheimer's disease-related pathologies in vitro and in the 3xTg-AD mouse model.

Janczura KJ, Volmar CH, Sartor GC, Rao SJ, Ricciardi NR, Lambert G, Brothers SP, Wahlestedt C.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11148-E11157. doi: 10.1073/pnas.1805436115. Epub 2018 Nov 5.

9.

Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma.

Lohse I, Al-Ali H, Volmar CH, D Alvarez Trotta A, Brothers SP, Capobianco AJ, Wahlestedt C.

PLoS One. 2018 Sep 13;13(9):e0203173. doi: 10.1371/journal.pone.0203173. eCollection 2018.

10.

EZH1 is an antipsychotic-sensitive epigenetic modulator of social and motivational behavior that is dysregulated in schizophrenia.

Johnstone AL, O'Reilly JJ, Patel AJ, Guo Z, Andrade NS, Magistri M, Nathanson L, Esanov R, Miller BH, Turecki G, Brothers SP, Zeier Z, Wahlestedt C.

Neurobiol Dis. 2018 Nov;119:149-158. doi: 10.1016/j.nbd.2018.08.005. Epub 2018 Aug 9.

PMID:
30099093
11.

Vitamin C Sensitizes Melanoma to BET Inhibitors.

Mustafi S, Camarena V, Volmar CH, Huff TC, Sant DW, Brothers SP, Liu ZJ, Wahlestedt C, Wang G.

Cancer Res. 2018 Jan 15;78(2):572-583. doi: 10.1158/0008-5472.CAN-17-2040. Epub 2017 Nov 27.

12.

Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.

Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C.

Leuk Res. 2018 Jan;64:34-41. doi: 10.1016/j.leukres.2017.11.008. Epub 2017 Nov 11.

13.

Neuropeptide Y Y2 antagonist treated ovariectomized mice exhibit greater bone mineral density.

Seldeen KL, Halley PG, Volmar CH, Rodríguez MA, Hernandez M, Pang M, Carlsson SK, Suva LJ, Wahlestedt C, Troen BR, Brothers SP.

Neuropeptides. 2018 Feb;67:45-55. doi: 10.1016/j.npep.2017.11.005. Epub 2017 Nov 7.

14.

M344 promotes nonamyloidogenic amyloid precursor protein processing while normalizing Alzheimer's disease genes and improving memory.

Volmar CH, Salah-Uddin H, Janczura KJ, Halley P, Lambert G, Wodrich A, Manoah S, Patel NH, Sartor GC, Mehta N, Miles NTH, Desse S, Dorcius D, Cameron MD, Brothers SP, Wahlestedt C.

Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9135-E9144. doi: 10.1073/pnas.1707544114. Epub 2017 Oct 9.

15.

Orphan diseases: state of the drug discovery art.

Volmar CH, Wahlestedt C, Brothers SP.

Wien Med Wochenschr. 2017 Jun;167(9-10):197-204. doi: 10.1007/s10354-015-0423-0. Epub 2016 Jan 27.

16.

Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice.

Sartor GC, Powell SK, Wiedner HJ, Wahlestedt C, Brothers SP.

Brain Res. 2016 Feb 1;1632:34-41. doi: 10.1016/j.brainres.2015.11.044. Epub 2015 Dec 3.

17.

Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.

Sartor GC, Powell SK, Brothers SP, Wahlestedt C.

J Neurosci. 2015 Nov 11;35(45):15062-72. doi: 10.1523/JNEUROSCI.0826-15.2015.

18.

Bromodomain inhibitors regulate the C9ORF72 locus in ALS.

Zeier Z, Esanov R, Belle KC, Volmar CH, Johnstone AL, Halley P, DeRosa BA, Khoury N, van Blitterswijk M, Rademakers R, Albert J, Brothers SP, Wuu J, Dykxhoorn DM, Benatar M, Wahlestedt C.

Exp Neurol. 2015 Sep;271:241-50. doi: 10.1016/j.expneurol.2015.06.017. Epub 2015 Jun 20.

19.

Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1.

Galoian K, Qureshi A, D'Ippolito G, Schiller PC, Molinari M, Johnstone AL, Brothers SP, Paz AC, Temple HT.

Int J Oncol. 2015 Aug;47(2):465-72. doi: 10.3892/ijo.2015.3054. Epub 2015 Jun 18.

20.

Emerging treatment strategies for glioblastoma multiforme.

Carlsson SK, Brothers SP, Wahlestedt C.

EMBO Mol Med. 2014 Nov;6(11):1359-70. doi: 10.15252/emmm.201302627. Review.

21.

Differential effects of the Gβ5-RGS7 complex on muscarinic M3 receptor-induced Ca2+ influx and release.

Karpinsky-Semper D, Volmar CH, Brothers SP, Slepak VZ.

Mol Pharmacol. 2014 May;85(5):758-68. doi: 10.1124/mol.114.091843. Epub 2014 Feb 28.

22.

BET bromodomain proteins are required for glioblastoma cell proliferation.

Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar RJ, Wahlestedt C, Ayad NG.

Epigenetics. 2014 Apr;9(4):611-20. doi: 10.4161/epi.27906. Epub 2014 Feb 19.

23.

Amygdala-dependent fear is regulated by Oprl1 in mice and humans with PTSD.

Andero R, Brothers SP, Jovanovic T, Chen YT, Salah-Uddin H, Cameron M, Bannister TD, Almli L, Stevens JS, Bradley B, Binder EB, Wahlestedt C, Ressler KJ.

Sci Transl Med. 2013 Jun 5;5(188):188ra73. doi: 10.1126/scitranslmed.3005656.

24.

Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor antagonists.

Mittapalli GK, Vellucci D, Yang J, Toussaint M, Brothers SP, Wahlestedt C, Roberts E.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):3916-20. doi: 10.1016/j.bmcl.2012.04.107. Epub 2012 Apr 30.

25.

Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation.

Modarresi F, Faghihi MA, Lopez-Toledano MA, Fatemi RP, Magistri M, Brothers SP, van der Brug MP, Wahlestedt C.

Nat Biotechnol. 2012 Mar 25;30(5):453-9. doi: 10.1038/nbt.2158.

26.

Probe Report for NPY-Y2 Receptor Antagonists.

Saldanha SA, Brothers SP, Spicer T, Cameron M, Mercer BA, Chase P, McDonald P, Wahlestedt C, Hodder PS.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2009 Jan 13 [updated 2010 Aug 6].

27.

Therapeutic potential of neuropeptide Y (NPY) receptor ligands.

Brothers SP, Wahlestedt C.

EMBO Mol Med. 2010 Nov;2(11):429-39. doi: 10.1002/emmm.201000100. Review.

28.

RNAi screen indicates widespread biological function for human natural antisense transcripts.

Faghihi MA, Kocerha J, Modarresi F, Engström PG, Chalk AM, Brothers SP, Koesema E, St Laurent G, Wahlestedt C.

PLoS One. 2010 Oct 4;5(10). pii: e13177. doi: 10.1371/journal.pone.0013177.

29.

Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Brothers SP, Saldanha SA, Spicer TP, Cameron M, Mercer BA, Chase P, McDonald P, Wahlestedt C, Hodder PS.

Mol Pharmacol. 2010 Jan;77(1):46-57. doi: 10.1124/mol.109.058677. Epub 2009 Oct 16.

30.

A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome.

Khalil AM, Faghihi MA, Modarresi F, Brothers SP, Wahlestedt C.

PLoS One. 2008 Jan 23;3(1):e1486. doi: 10.1371/journal.pone.0001486.

31.

Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.

Janovick JA, Brothers SP, Cornea A, Bush E, Goulet MT, Ashton WT, Sauer DR, Haviv F, Greer J, Conn PM.

Mol Cell Endocrinol. 2007 Jun 30;272(1-2):77-85. Epub 2007 May 3.

32.

Specializations of a G-protein-coupled receptor that appear to aid with detection of frequency-modulated signals from its ligand.

Janovick JA, Brothers SP, Knollman PE, Conn PM.

FASEB J. 2007 Feb;21(2):384-92. Epub 2006 Dec 15.

PMID:
17172315
33.

Calnexin regulated gonadotropin-releasing hormone receptor plasma membrane expression.

Brothers SP, Janovick JA, Conn PM.

J Mol Endocrinol. 2006 Dec;37(3):479-88.

PMID:
17170088
34.

'Effective inefficiency': cellular control of protein trafficking as a mechanism of post-translational regulation.

Conn PM, Janovick JA, Brothers SP, Knollman PE.

J Endocrinol. 2006 Jul;190(1):13-6.

PMID:
16837606
35.

Protein folding as posttranslational regulation: evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor.

Conn PM, Knollman PE, Brothers SP, Janovick JA.

Mol Endocrinol. 2006 Dec;20(12):3035-41. Epub 2006 Mar 23. Review.

PMID:
16556733
36.

Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression: molecular basis of an evolved strategy.

Janovick JA, Knollman PE, Brothers SP, Ayala-Yáñez R, Aziz AS, Conn PM.

J Biol Chem. 2006 Mar 31;281(13):8417-25. Epub 2006 Jan 30.

37.

Parallel regulation of membrane trafficking and dominant-negative effects by misrouted gonadotropin-releasing hormone receptor mutants.

Knollman PE, Janovick JA, Brothers SP, Conn PM.

J Biol Chem. 2005 Jul 1;280(26):24506-14. Epub 2005 May 10.

38.

Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease.

Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM.

Traffic. 2004 Nov;5(11):821-37. Review.

39.
41.

A Galphas mutation (D229S) differentially effects gonadotropin-releasing hormone receptor regulation by RGS10, RGS3 and RGS3T.

Castro-Fernández C, Brothers SP, Michael Conn P.

Mol Cell Endocrinol. 2003 Feb 28;200(1-2):119-26.

PMID:
12644305
42.

Conserved mammalian gonadotropin-releasing hormone receptor carboxyl terminal amino acids regulate ligand binding, effector coupling and internalization.

Brothers SP, Janovick JA, Maya-Nunez G, Cornea A, Han XB, Conn PM.

Mol Cell Endocrinol. 2002 Apr 25;190(1-2):19-27.

PMID:
11997175
43.

Regulation of RGS3 and RGS10 palmitoylation by GnRH.

Castro-Fernández C, Janovick JA, Brothers SP, Fisher RA, Ji TH, Conn PM.

Endocrinology. 2002 Apr;143(4):1310-7.

PMID:
11897687

Supplemental Content

Loading ...
Support Center